Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: main concepts for anesthetists

  • Bibiana Escobar a. Anaesthesia Department, Medical School, Universidad Nacional de Colombia. Bogotá, Colombia. b. Anaesthesia and Perioperative Medicine Service. Instituto Nacional de Cancerología. Bogotá, Colombia.
  • Paula Medina-Piedrahita Anaesthesia Department, Medical School, Universidad Nacional de Colombia. Bogotá, Colombia.
  • Paula Gómez-Henao Anaesthesia and Perioperative Medicine Service. Instituto Nacional de Cancerología. Bogotá, Colombia.
  • Andres Higuera-Palacio Anaesthesia and Perioperative Medicine Service. Instituto Nacional de Cancerología. Bogotá, Colombia.
  • Mauricio García-Mora Breast and Soft Tissue Surgery Service, Instituto Nacional de Cancerología. Bogotá, Colombia
  • Joaquín Octavio Ruiz-Villa Anaesthesia Department, Medical School, Universidad Nacional de Colombia. Bogotá, Colombia.
  • Crystian Borrero-Cortés Anaesthesia Department, Medical School, Universidad Nacional de Colombia. Bogotá, Colombia.
Keywords: Hyperthermia, Induced; Drug Therapy, Combination, Anesthesiology, Intestinal Neoplasms, Peritoneal Neoplasms

Abstract

Introduction:

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex therapeutic procedure used to complement cytoreductive surgery and intravenous chemotherapy for the management of primary peritoneal neoplasms and peritoneal carcinomatosis.

Objectives:

To review considerations regarding the surgical procedure, physiological changes associated with fluid, blood and protein loss, increase in intra-abdominal pressure, metabolic rate, and systemic hyperthermia, from the perspective of the anesthetist.

Methods:

A nonsystematic search was conducted in the Medline/PUBMED and Google Academics databases using the terms cytoreductive surgery, hyperthermia, HIPEC, peritoneal carcinomatosis, and Sugarbaker. No limits for publication dates were used. The articles were reviewed independently by each of the authors, and the final text was edited and approved by the main author.

Results:

Overall, 151 articles were identified, and, of these, 64 were included in the review. The aspects studied included the surgical technique, physiological changes during the procedure, and anesthetic management.

Conclusion:

Cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy is a therapeutic option for patients with peritoneal carcinomatosis. This procedure involves risks for the patient, first because of an initial phase which involves fluid and blood loss, and, second, because the hyperthermic phase gives rise to a hyperdynamic state with hemodynamic instability. Anesthetists must be familiar with the basic aspects of management to reduce complications and improve patient outcomes.

References

1. Spratt JS, Adcock RA, Sherrill W, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256-260.

2. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29-42.

3. Sugarbaker PH, Landy D, Pascal R. Intraperitoneal chemotherapy for peritoneal carcinomatosis from colonic or appendiceal cystadenocarcinoma: rationale and results of treatment. Prog Clin Biol Res 1990;354B:141-170.

4. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg 1999;384:576-587.

5. González-Moreno S. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2010;2:68.

6. Chu D, Lang N, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. Cancer 1989;63:364-367.

7. Verwaal VJ, Bruin S, Boot H, et al. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-2432.

8. Weber T, Roitman M, Link KH. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Clin Colorectal Cancer 2012;11:167-176.

9. Reuter NP, MacGregor JM, Woodall CE, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg 2008;196:909-914.

10. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyper-thermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 2009;249:900-907.

11. Roviello F, Caruso S, Marrelli D, et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 2011;20:e38-e54.

12. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007;14:128-133.

13. Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol 2014;40:1605-1613.

14. Esquivel J, Farinetti A, Sugarbaker PH. [Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed]. G Chir 1999;20:81-86.

15. Macri A. Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World J Gastrointest Oncol 2011;3:169.

16. Huang C-Q Min Y, Wang S-Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 2017;8:55657-55683.

17. Hornung M, Werner JM, Schlitt HJ. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Expert Rev Anticancer Ther 2017;17:841-850.

18. Li Y, Zhou Y-F, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol 2016;22:6906.

19. Turaga K, Levine E, Barone R, et al. Consensus guidelines from the american society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2014;21:1501-1505.

20. Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol 2016;7:29-44.

21. Raspe C, Piso P, Wiesenack C, et al. Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 2012;25:348-355.

22. Schmidt C, Creutzenberg M, Piso P, et al. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 2008;63:389-395.

23. Bell JC, Rylah BG, Chambers RW, et al. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience. Ann Surg Oncol 2012;19:4244-4251.

24. Shime N, Lee M, Hatanaka T. Cardiovascular changes during continuous hyperthermic peritoneal perfusion. Anesth Analg 1994;78:938-942.

25. Kanakoudis F, Petrou A, Michaloudis D, et al. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy: haemodynamic changes, oxygen consumption and delivery. Anaesthesia 1996;51:1033-1036.

26. Li S, Zhang Y, Sun J, et al. Safe temperature range for intraoperative and early postoperative continuous hyperthermic intraperitoneal perfusion in a swine model of experimental distal gastrectomy with Billroth II reconstruction. J Transl Med 2013;11:181.

27. Esquivel J, Angulo F, Bland RK, et al. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open “coliseum technique”. Ann Surg Oncol 2000;7:296-300.

28. McDougall EM, Monk TG, Wolf JSJ, et al. The effect of prolonged pneumoperitoneum on renal function in an animal model. J Am Coll Surg 1996;182:317-328.

29. Demyttenaere S, Feldman LS, Fried GM. Effect of pneumoper-itoneum on renal perfusion and function: a systematic review. Surg Endosc 2007;21:152-160.

30. Wauters J, Claus P, Brosens N, et al. Pathophysiology of renal hemodynamics and renal cortical microcirculation in a porcine model of elevated intra-abdominal pressure. J Trauma 2009;66:713-719.

31. Kashtan J, Green JF, Parsons EQ, et al. Hemodynamic effect of increased abdominal pressure. J Surg Res 1981;30:249-255.

32. Gerges FJ, Kanazi GE, Jabbour-Khoury SI. Anesthesia for laparos-copy: a review. J Clin Anesth 2006;18:67-78.

33. Oseledchyk A, Zivanovic O. Intraoperative hyperthermic intra-peritoneal chemotherapy in patients with advanced ovarian cancer. Oncology (Williston Park) 2015;29:695-701.

34. Talmor D, Kelly B. How to better identify patients at high risk of postoperative complications? Curr Opin Crit Care 2017;23:417-123.

35. Rothfield KP, Crowley K. Anesthesia considerations during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Oncol Clin N Am 2012;21:533-541.

36. Webb CAJ, Weyker PD, Moitra VK, et al. An overview of cytoreductive surgery and hyperthermic intraperitoneal chemo-perfusion for the anesthesiologist. Anesth Analg 2013;116: 924-931.

37. Schmidt C, Moritz S, Rath S, et al. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Surg Oncol 2009;100:297-301.

38. Holly TA, Kane GC, Joseph E, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary. J Nucl Cardiol 2015;22:162-215.

39. Sahai SK, Zalpour A, Rozner MA. Preoperative evaluation of the oncology patient. Anesthesiol Clin 2009;27:805-822.

40. Owusu-Agyemang P, Arunkumar R, Green H, et al. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Ann Surg Oncol 2012;19:2652-2656.

41. Josephs SA, Thakar CV. Perioperative risk assessment, prevention, and treatment of acute kidney injury. Int Anesthesiol Clin 2009;47:89-105.

42. Committee on Standards and Practice Parameters (CSPP). Standards for Basic Anesthetic Monitoring [Internet]; 2015 (p. 1-4). [Cited 10 Nov 17]. Available at: http://www.asahq.org/quality-and-practice-management/standards-guidelines-and-related-resources/standards-for-basic-anesthetic-monitoring.

43. Cafiero T, Di Iorio C, Di Minno RM, et al. Non-invasive cardiac monitoring by aortic blood flow determination in patients undergoing hyperthermic intraperitoneal intraoperative chemotherapy. Minerva Anestesiol 2006;72:207-215.

44. Thanigaimani K, Mohamed F, Cecil T, et al. The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy. Color Dis 2013;15:1537-1542.

45. Reynolds L, Beckmann J, Kurz A. Perioperative complications of hypothermia. Best Pract Res Clin Anaesthesiol 2008;22:645-657.

46. Sessler DI. Perioperative thermoregulation and heat balance. Lancet 2016;387:2655-2664.

47. Eng OS, Dumitra S, O’Leary M, et al. Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. JAMA Surg 2017;152:1156-1160.

48. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia 2010;65:283-293.

49. Chenitz KB, Lane-Fall MB, Chertow GM, et al. Decreased urine output and acute kidney injury in the postanesthesia care unit. Anesthesiol Clin 2012;30:513-526.

50. Guo C, Wei Q, Su Y, et al. SUMOylation occurs in acute kidney injury and plays a cytoprotective role. Biochim Biophys Acta 2015;1852:482-489.

51. Bulacio RP, Anzai N, Ouchi M, et al. Organic anion transporter 5 (Oat5) urinary excretion is a specific biomarker of kidney injury: evaluation of urinary excretion of exosomal Oat5 after N-acetylcysteine prevention of cisplatin induced nephrotoxicity. Chem Res Toxicol 2015;28:1595-1602.

52. Sooriyaarachchi M, Narendran A, Gailer J. N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro. Metallomics 2013;5:197-207.

53. Shalby AB, AssafN, Ahmed HH. Possible mechanisms for N-acetyl cysteine and taurine in ameliorating acute renal failure induced by cisplatin in rats. Toxicol Mech Methods 2011;21:538-546.

54. Groeneveld ABJ, Navickis RJ, Wilkes MM. Update on the comparative safety of colloids. Ann Surg 2011;253:470-483.

55. Sheshadri DB, Chakravarthy MR. Anaesthetic considerations in the perioperative management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Indian J Surg Oncol 2016;7:236-243.

56. Sudaarshan G, Crawford D. Anaesthesia for intraperitoneal hyperthermic perfusion. Anaesthesia 1992;47:483-485.

57. De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 2008;28:61-66.

58. Thix CA, Königsrainer I, Kind R, et al. Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy. Anaesthesia 2009;64:1134-1136.

59. de la Chapelle A, Perus O, Soubielle J, et al. High potential for epidural analgesia neuraxial block-associated hypotension in conjunction with heated intraoperative intraperitoneal chemotherapy. Reg Anesth Pain Med 2005;30:313-314.

60. Piccioni F, Casiraghi C, Fumagalli L, et al. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. Int J Surg 2015;16 (Part A):99-106.

61. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperito-neal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155-162.

62. Blumenthal S, Min K, Nadig M, et al. Double epidural catheter with ropivacaine versus intravenous morphine: a comparison for postoperative analgesia after scoliosis correction surgery. Anesthesiology 2005;102:175-180.

63. Desgranges F-P, Steghens A, Rosay H, et al. [Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique?]. Ann Fr Anesth Reanim 2012;31:53-59.

64. Schmidt C, Steinke T, Moritz S, et al. Thoracic epidural anesthesia in patients with cytoreductive surgery and HIPEC. J Surg Oncol 2010;102:545-546.
How to Cite
1.
Escobar B, Medina-Piedrahita P, Gómez-Henao P, Higuera-Palacio A, García-Mora M, Ruiz-Villa JO, Borrero-Cortés C. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: main concepts for anesthetists. Colomb. J. Anesthesiol. [Internet]. 2018Apr.1 [cited 2021Feb.28];46(2):134-42. Available from: https://www.revcolanest.com.co/index.php/rca/article/view/209

Downloads

Download data is not yet available.
Published
2018-04-01
How to Cite
1.
Escobar B, Medina-Piedrahita P, Gómez-Henao P, Higuera-Palacio A, García-Mora M, Ruiz-Villa JO, Borrero-Cortés C. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: main concepts for anesthetists. Colomb. J. Anesthesiol. [Internet]. 2018Apr.1 [cited 2021Feb.28];46(2):134-42. Available from: https://www.revcolanest.com.co/index.php/rca/article/view/209
Section
Narrative review

More on this topic